1

ALK-Abelló

#2706

Rank

$4.96B

Marketcap

DK Denmark

Country

ALK-Abelló
Leadership team

Mr. Carsten Hellmann (Pres, CEO & Member of Management Board)

Mr. Soren Jelert (Group CFO, Exec. VP & Member of Management Board)

Mr. Henrik Jacobi (Exec. VP of R&D and Member of Board of Management)

Products/ Services
Biotechnology, Health Care, Health Diagnostics, Medical, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Hørsholm, Hovedstaden, Denmark
Established
1923
Net Income
20M - 100M
Revenue
500M - 1B
Traded as
ALK-B.CO
Social Media
Overview
Location
Summary
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
History

ALK-Abello dates back to 1923 when Denmark’s first allergen extracts were produced at the pharmacy of the Copenhagen University Hospital. The company was subsequently established as Allergologisk Laboratorium København. The company has since focused on mapping the mechanisms of allergic impact on the immune system in order to develop new and improved allergy therapies. The research focuses on prevention, treatment, and management of allergies, especially hay fever and asthma. In 1925 Juan Abello Pascual founded Abello Pharmaceuticals in Spain.

In 1978, ALK released the first standardized line of products for the treatment of allergies. In 1992 ALK and Abello merged. In the 1990s, ALK was the first company to launch sublingual immunotherapy drops . In recent years, ALK’s research and development strategy has been focused on introducing a range of sublingual immunotherapy tablets . The first, for grass pollen allergy, was launched in 2006, and was followed by SLIT-tablets for ragweed pollen allergy in 2014 and house dust mite allergy in 2016. The company is part-owned by the Lundbeck Foundation, however is also a publicly traded entity.

Mission
Our mission is to improve the lives of our patients and secure the future of allergy prevention, diagnosis, and treatment.
Vision
We aim to become a leading player in the global allergy field, with products and expertise that help people understand, manage and prevent allergies.
Key Team

Mr. Søren Daniel Niegel (Exec. VP of Commercial Operations & Member of Management Board)

Ms. Katja Barnkob Thalund (Project Director of Global CMC Devel. & Employee-elected Director)

Mr. Per Plotnikof (VP of Corp. Communications, Investor Relations & Strategic Planning and Head of IR)

Prof. Hendrik Kees Kam Nolte M.D., Ph.D. (Sr. VP of Research & Devel. - North America and International Markets)

Mr. Christian G. Houghton (Head of Product Supply)

Mr. Miles Guralnick (Pres of ALK Abelló Source Materials Inc)

Recognition and Awards
ALK-Abelló has earned numerous awards and recognitions, including the 2017 Biological of the Year Award from the European Respiratory Society, the 2018 World Allergy Innovation of the Year Award from the World Allergy Organization, and the 2019 World Environment Award for Innovation in Allergy Prevention from the World Health Organization.
References
ALK-Abelló
Leadership team

Mr. Carsten Hellmann (Pres, CEO & Member of Management Board)

Mr. Soren Jelert (Group CFO, Exec. VP & Member of Management Board)

Mr. Henrik Jacobi (Exec. VP of R&D and Member of Board of Management)

Products/ Services
Biotechnology, Health Care, Health Diagnostics, Medical, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Hørsholm, Hovedstaden, Denmark
Established
1923
Net Income
20M - 100M
Revenue
500M - 1B
Traded as
ALK-B.CO
Social Media